Elan Corp, plc (ADR) (ELN)

bhessel (90.86) Submitted: 12/11/07 10:16 AM : Start Price: $13.84 ELN Score: -2.84

[written 6 Apr 07]

Élan (ELN) is a biotech company based in Ireland, and constitutes a poster child for the vagaries of speculation. At the beginning of the decade, the company had a marketcap around $20B and shares traded as high as $61 in June 200...

Report this Post Replies: 9 | Reply | Permalink

KatWoman50 (27.57) Submitted: 4/20/07 3:37 PM : Start Price: $14.94 ELN Score: -5.89

Elan has 4 drugs and 1 technology being marketed in the US and Europe.

Tysabri has been reapproved in the US after more testing for use in relapsing MS. In a 2 year study, a 56% decrease in MS relapses was recorded. In a study published 4/17/07, Ty...

Report this Post Replies: 0 | Reply | Permalink

NetscribeBiotech (87.17) Submitted: 6/05/07 6:55 AM : Start Price: $19.84 ELN Score: -19.27

The year 2007 started of greatly for Elan with the drug Tysabri bringing in close to $26 million in the first quarter. This figure is phenomenal when compared to the $28 million sales of the same drug during the half year of 2006 (it was introduced i...

Report this Post Replies: 1 | Reply | Permalink

BeautifulPlumage (99.96) Submitted: 7/30/08 3:02 PM : Start Price: $20.37 ELN Score: -34.71

The stock was a little overpriced, but a 40% drop on OK news from its phase 2 trial for bapineuzumab puts it right back in the 'reasonably valued' class, and although the chances of gigantic success from bap have taken a baby step backwards, there is...

Report this Post Replies: 0 | Reply | Permalink

shoulda2003 (25.50) Submitted: 12/27/06 10:03 PM : Start Price: $14.36 ELN Score: -6.06

tysabri uptake, alzheimer's pipeline

Report this Post Replies: 0 | Reply | Permalink

PaddyFahey (95.89) Submitted: 9/25/06 10:50 PM : Start Price: $15.81 ELN Score: -17.75

Elan's Tysabri is only the tip of this Iceberg and a large chunk of ice it is. If Tysabri reaches full potential an absolutely conservative estimate is $30 a share. In addition to Tysabri are two other aspects to this business;
1- Alzheimers Drug so...

Report this Post Replies: 0 | Reply | Permalink

TMFBreakerOrion (27.26) Submitted: 6/21/06 7:45 PM : Start Price: $17.43 ELN Score: -25.89

MS is such a terrible disease and the current treatments just aren't effective enough. Tysabri isn't really effective enough either (as it's not a cure) but it's tremendously better than the alternatives currently available. Once the MS community s...

Report this Post Replies: 0 | Reply | Permalink

kahunacfa (< 20) Submitted: 3/15/07 2:02 PM : Start Price: $12.68 ELN Score: 1.35

The FDA recently voted that Tysabri should be made available to patients with MS who have not tried other available first-line therapies and that Tysabri should be returned to the market. This decision should have a favorable impact on the shares of ...

Report this Post Replies: 0 | Reply | Permalink

northcutt0 (< 20) Submitted: 8/25/06 1:04 AM : Start Price: $15.47 ELN Score: -18.18

It's hard to think of a biotech company as a investment for all economic "weather" environments. Believe me, I have trouble myself. They have a drug approved, Tysabri, approved in both the USA and EU for treatment of MS. People need this drug, bes...

Report this Post Replies: 0 | Reply | Permalink

Providence (< 20) Submitted: 10/19/06 12:05 PM : Start Price: $15.54 ELN Score: 14.47

Elan not only has Tysabri for MS, they have a monster Alzheimer's program. If all goes well, they will be first to market with one or two dominating therapies. This is a 100 billion market. They will own the space.

On top of MS and AD, look for deve...

Report this Post Replies: 1 | Reply | Permalink